-
公开(公告)号:US09862716B2
公开(公告)日:2018-01-09
申请号:US15129206
申请日:2015-03-23
Applicant: Merck Sharp & Dohme Corp.
Inventor: Helen Mitchell , Mark E. Fraley , Andrew J. Cooke , Craig A. Stump , Yi-Heng Chen , Xu-Fang Zhang , Casey C. McComas , Kathy Schirripa , Melody McWherter , Swati P. Mercer , Keith P. Moore , Ping Liu , Harold B. Wood , Chun Sing Li , Qinghua Mao , Douglas C. Beshore
IPC: C07D471/04 , C07D513/04
CPC classification number: C07D403/12 , C07D401/12 , C07D403/14 , C07D471/04 , C07D487/04 , C07D513/04
Abstract: The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
-
公开(公告)号:US09708308B2
公开(公告)日:2017-07-18
申请号:US14652237
申请日:2013-12-16
Inventor: Cameron James Smith , John Qiang Tan , Ting Zhang , James Balkovec , William John Greenlee , Liangqin Guo , Yi-Heng Chen , Yili Chen , Jiayi Xu , Samuel Chackalamannil , Tomokazu Hirabayashi , Hiroshi Nagasue , Kouki Ogawa
IPC: C07D471/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D498/04
CPC classification number: C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D498/04
Abstract: The present invention provides a compound of Formula (I) wherein R1 is H or C1-6 alkyl, R2, is H or C1-6 alkyl or CH2OH, R3 is H or C1-6 alkyl, and R4 is H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, then R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl or —CH2OH, and when R2, R3, and R4 are H, then R1 is C1-6 alkyl; A is 1) a 9-10 membered bicyclic heterocycle having 1-3 heteroatoms independently selected from N, S and O, which 9-10 membered bicyclic heterocycle is unsubstituted or substituted with R5 and unsubstituted or substituted with R6 and unsubstituted or substituted with NH2, or 2) a 6-9 membered monocyclic or bicyclic carbocyclic ring system unsubstituted or substituted with R5, unsubstituted or substituted with R6, and unsubstituted or substituted with —CH2NH2; and B is 1) a 5- or 6-membered monocyclic heterocycle having 1 or 2 heteroatoms independently selected from N, S or O, which is unsubstituted or substituted on a carbon or nitrogen atom with R7, unsubstituted or substituted on a carbon or nitrogen atom with R8, and unsubstituted or substituted on a carbon or nitrogen atom with R9, or 2) an 8- or 9-membered fused bicyclic heterocycle having 1, 2 or 3 nitrogen atoms which is unsubstituted or substituted on a carbon or nitrogen atom with R7, and unsubstituted or substituted on a carbon or nitrogen atom with R8; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses.
-
公开(公告)号:US20220259188A1
公开(公告)日:2022-08-18
申请号:US17614732
申请日:2020-06-01
Applicant: Hua ZHOU , John J. ACTON, III , Michael J. ARDOLINO , Yi-Heng CHEN , Peter H. FULLER , Anmol GULATI , Rebecca Elizabeth JOHNSON , William P. KAPLAN , Solomon D. KATTAR , Mitchell H. KEYLOR , Derun LI , Kaitlyn Marie LOGAN , Min LU , Gregori J. MORRIELLO , Santhosh F. NEELAMKAVIL , Barbara PIO , Nunzio SCIAMMETTA , Vladimir SIMOV , Jing SU , Luis TORRES , Xin YAN , Merck Sharp & Dohme Corp.
Inventor: Hua Zhou , John J. Acton, III , Michael J. Ardolino , Yi-Heng Chen , Peter H. Fuller , Anmol Gulati , Rebecca Elizabeth Johnson , William P. Kaplan , Solomon D. Kattar , Mitchell H. Keylor , Derun Li , Kaitlyn Marie Logan , Min Lu , Gregori J. Morriello , Santhosh F. Neelamkavil , Barbara Pio , Nunzio Sciammetta , Vladimir Simov , Jing Su , Luis Torres , Xin Yan
IPC: C07D405/14 , C07D487/08 , C07D409/14 , C07D403/04 , C07D403/14 , C07D498/04 , C07D498/08 , C07D487/10 , C07D401/14 , C07D471/10 , C07D491/107 , C07D471/04 , C07D487/04 , A61P25/16
Abstract: The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.
-
公开(公告)号:US09695198B2
公开(公告)日:2017-07-04
申请号:US14652150
申请日:2013-12-16
Applicant: Cameron James Smith , Edward Sherer , Louis-Charles Campeau , James Balkovec , William John Greenlee , Derun Li , Liangqin Guo , Tin-Yau Chan , Yi-Heng Chen , Yili Chen , Samuel Chackalamannil , John Qiang Tan , Tomokazu Hirabayashi , Mika Sekioka , MERCK SHARP & DOHME CORP. , MOCHIDA PHARMACEUTICAL CO., LTD.
Inventor: Cameron James Smith , Edward Sherer , Louis-Charles Campeau , James Balkovec , William John Greenlee , Derun Li , Liangqin Guo , Tin-Yau Chan , Yi-Heng Chen , Yili Chen , Samuel Chackalamannil , John Qiang Tan , Tomokazu Hirabayashi , Mika Sekioka
IPC: C07D413/14 , C07D417/06 , C07D498/04 , C07D513/04 , C07D413/12 , C07D471/04 , C07D413/06
CPC classification number: C07D513/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D471/04 , C07D498/04
Abstract: The present invention provides a compound of Formula (I) where A is a heterocycle ring system and B is a heterocycle ring system or aryl ring system, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.
-
公开(公告)号:US20160075724A1
公开(公告)日:2016-03-17
申请号:US14875438
申请日:2015-10-05
Applicant: Merck Sharp & Dohme Corp.
Inventor: Amjad Ali , Joann M. Napolitano , Qiaolin Deng , Zhijian Lu , Peter J. Sinclair , Gayle E. Hallet , Christopher F. Thompson , Nazia Quraishi , Cameron J. Smith , Julianne A. Hunt , Adrian A. Dowst , Yi-Heng Chen , Hong Li
IPC: C07F7/10 , C07D413/04 , C07D233/32 , C07D417/10 , C07D285/06 , C07D207/26 , C07D233/52 , C07D413/10 , C07D263/22 , C07D401/04
CPC classification number: C07F7/10 , A61K31/4015 , A61K31/4166 , A61K31/4168 , A61K31/421 , A61K31/422 , A61K31/427 , A61K31/433 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K45/06 , C07D207/26 , C07D207/27 , C07D233/32 , C07D233/38 , C07D233/50 , C07D233/52 , C07D263/04 , C07D263/20 , C07D263/22 , C07D263/24 , C07D263/26 , C07D285/06 , C07D285/10 , C07D401/04 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/04 , C07D417/10
Abstract: Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.
Abstract translation: 具有式I结构的化合物,包括化合物的药学上可接受的盐,是CETP抑制剂,可用于升高HDL-胆固醇,降低LDL-胆固醇,以及用于治疗或预防动脉粥样硬化。在式I化合物中,B或 R2是具有邻芳基,杂环,苯并杂环或苯并环烷基取代基的苯基,并且在5元环上的另一个位置具有直接连接到环上或连接到环上的芳族,杂环,环烷基,苯并杂环或苯并环烷基取代基 通过-CH2-。
-
公开(公告)号:US20150329562A1
公开(公告)日:2015-11-19
申请号:US14652174
申请日:2013-12-16
Applicant: MERCK SHARP & DOHME CORP.
Inventor: Cameron James Smith , John Qiang Tan , Ting Zhang , James Balkovec , William John Greenlee , Liangqin Guo , Yi-Heng Chen , Yili Chen , Samuel Chackalamannil , Tomokazu Hirabayashi , Mika Sekioka
IPC: C07D513/04 , C07D413/14
CPC classification number: C07D413/14 , C07D413/12 , C07D513/04
Abstract: The present invention provides a compound of Formula (I) wherein R1, R2, R3 and R4 are independently H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl, and when R2, R3, and R4 are H, R is C1-6 alkyl; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.
Abstract translation: 本发明提供式(I)的化合物,其中R 1,R 2,R 3和R 4独立地为H或C 1-6烷基,条件是当R 1,R 2和R 3为H时,R 4为C 1-6烷基, 中,R 2和R 4为H,R 3为C 1-6烷基,当R 1,R 3和R 4为H时,R 2为C 1-6烷基,当R 2,R 3和R 4为H时,R为C 1-6烷基 ; 和包含一种或多种所述化合物的药物组合物,以及使用所述化合物治疗或预防血栓形成,栓塞,高凝状态或纤维化改变的方法。
-
公开(公告)号:US10189819B2
公开(公告)日:2019-01-29
申请号:US15534029
申请日:2015-12-07
Applicant: MERCK SHARP & DOHME CORP. , MOCHIDA PHARMACEUTICAL CO., LTD
Inventor: Ting Zhang , Yi-Heng Chen , Liangqin Guo , Alan Hruza , Tianying Jian , Bing Li , Dongfang Meng , Dann L. Parker , Edward C. Sherer , Harold B. Wood , Isao Sakurada
IPC: C07D403/12 , C07D401/14 , C07D401/12 , C07D471/04 , C07D413/14 , C07D413/12 , C07D417/12
Abstract: The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.
-
公开(公告)号:US09815846B2
公开(公告)日:2017-11-14
申请号:US15128689
申请日:2015-03-23
Applicant: Merck Sharp & Dohme Corp. , MSD R & D (China) Co., LTD.
Inventor: Helen Mitchell , Mark E. Fraley , Andrew J. Cooke , Craig A. Stump , Yi-Heng Chen , Xu-Fang Zhang , Casey C. McComas , Kathy Schirripa , Melody McWherter , Swati P. Mercer , Kerim Babaoglu , Dongfang Meng , Jane Wu , Ping Liu , Harold B. Wood , Jianming Bao , Chun Sing Li , Qinghua Mao , Zhiqi Qi
IPC: C07D491/107 , C07C233/66 , C07D213/75 , C07D403/12 , C07D401/12 , C07D417/12 , C07D239/42 , C07D401/04 , C07D413/12 , C07D417/14 , C07D401/14 , C07D405/12 , C07D413/14 , C07D403/14 , C07D405/14 , C07D471/04 , C07D401/06 , C07D413/06 , C07D403/06
CPC classification number: C07D491/107 , C07C233/66 , C07D213/75 , C07D231/12 , C07D239/42 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04
Abstract: The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
-
公开(公告)号:US10428076B2
公开(公告)日:2019-10-01
申请号:US16019964
申请日:2018-06-27
Applicant: Merck Sharp & Dohme Corp.
Inventor: Raphaelle Berger , Yi-Heng Chen , Guoqing Li , Joie Garfunkle , Hong-Dong Li , Shouwu Miao , Subharekha Raghavan , Cameron J. Smith , John Stelmach , Alan Whitehead , Rui Zhang , Yong Zhang , Jianmin Fu , Gang Ji , Falong Jiang
IPC: C07D487/04 , C07D519/00 , A61K31/519 , A61K45/06
Abstract: The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.
-
公开(公告)号:US20180305366A1
公开(公告)日:2018-10-25
申请号:US16019964
申请日:2018-06-27
Applicant: Merck Sharp & Dohme Corp.
Inventor: Raphaelle Berger , Yi-Heng Chen , Guoqing Li , Joie Garfunkle , Hong-Dong Li , Shouwu Miao , Subharekha Raghavan , Cameron J. Smith , John Stelmach , Alan Whitehead , Rui Zhang , Yong Zhang , Jianmin Fu , Gang Ji , Falong Jiang
IPC: C07D487/04 , A61K31/519 , C07D519/00 , A61K45/06
CPC classification number: C07D487/04 , A61K31/519 , A61K45/06 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , C07D519/00
Abstract: The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.
-
-
-
-
-
-
-
-
-